Regenxbio Inc (RGNX) 13F Filing Data & Analysis (Q2 2026)

RGNX ranks #3406 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

RGNX is a top-conviction position for 22nw, LP — at 5.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in RGNX belongs to BlackRock, Inc., but the position matters far more to 22nw, LP, who has 5.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

David Shaw has added to its RGNX position for two straight quarters, increasing it by $7.6M to reach $8.5M today.

JPMorgan has trimmed its RGNX position for two straight quarters, cutting it by $25.0M while still holding $26.2M.

RGNX is up 3% today, and institutions have been net buyers of $41.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

RGNX reported a net loss of $196.4M over the trailing twelve months.

• Not yet profitable — net loss of $196.4M over the trailing twelve months
• Revenue grew 12.0% year over year
• Net income declined year over year, from -$175.6M to -$196.4M
• Operating cash flow was negative, using $124.0M in cash
• Current ratio of 2.38x — enough short-term assets to cover short-term liabilities
• Liabilities run 3.41x equity — a highly leveraged balance sheet worth noting